Mark Bercy

Mark Bercy has extensive work experience in the pharmaceutical industry, starting in 2007. Mark worked as a Drug Safety Associate II at EMD Serono from September 2007 to September 2009. Mark then joined Genzyme as a Global Patient Safety Associate II from September 2009 to February 2012. Mark then moved to ARIAD Pharmaceuticals, Inc., where they held various roles in Pharmacovigilance from 2012 to 2017, including Pharmacovigilance Specialist II, Manager, and Senior Manager.

In 2017, Mark founded eCRO Pharma, a strategically focused resourcing organization that connects professionals and consultants in the pharmaceutical and biotech industries. Mark managed the company until October 2022.

From December 2018 to February 2023, Mark worked as a Sr. Manager at Dicerna Pharmaceuticals, Inc. Currently, they are an Associate Director of Drug Safety Operations at Kura Oncology, Inc., starting from January 2023.

Throughout their career, Mark has gained expertise in drug safety operations, pharmacovigilance, and quality assurance.

Mark Bercy attended Brandeis University from 2003 to 2007. During this time, they did not pursue a specific degree or field of study. However, at some point after their initial enrollment, Mark obtained a Bachelor's degree from Brandeis University. No further information regarding the specific field of study or duration of the degree program is provided.